Coordination Pharmaceuticals (CPI) has dosed the first patient in a Phase I study of nanoscale coordination polymer (NCP) CPI-200 in patients with advanced tumours.
CPI-200 contains two new molecular entities (NMEs) with synergistic anti-tumour activities.
The prospective, open-label, single-arm, non-randomised study will evaluate CPI-200 in patients with advanced tumours.
The trial’s primary objectives include determining maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary anti-tumour activity of CPI-200.
Secondary objectives of the trial are evaluating the PK of CPI-200, clinical response, and resolution of symptoms after CPI-200 treatment.
RiMO founder and chairman Wenbin Lin said: “Initiation of this study represents a significant milestone for CPI as CPI-200 is the company’s third candidate to enter clinical studies in the past year.
“We believe our two innovative technology platforms have the potential to change treatment paradigms for multiple cancer types and significantly benefit patients.”
CPI is also conducting a Phase I study of CPI-100 and a prospective, open-label, single-arm, non-randomised study of RiMO-301 in patients with advanced tumours.
CPI-100 will be evaluated in patients with advanced tumours as part of the prospective, open-label, single-arm, non-randomised study. It is administered through intravenous infusion in a 3+3 study design to identify the maximum tolerated dose (MTD).
CPI-100 also comprises two synergistic NMEs to activate tumour microenvironments for combination therapy with an immune checkpoint inhibitor.
RiMO-301 elicits unprecedented radiotherapy-radiodynamic therapy (RT-RDT) to improve the efficacy of X-ray radiotherapy.
A single escalation dose of RiMO-301 is intratumorally injected in a 3+3 study design to identify the recommended dose and dosing volumes.